TITLE

Review: Dipyridamole given with or without aspirin reduces recurrent stroke

AUTHOR(S)
Hankey, Graeme J.
PUB. DATE
July 2005
SOURCE
ACP Journal Club;Jul/Aug2005, Vol. 143 Issue 1, p25
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
This article presents information on a study related to dipyridamole for preventing recurrent ischemic stroke and other vascular events. Randomized controlled trials evaluated dipyridamole for secondary prevention of stroke in patients with previous cerebrovascular disease. Study quality was assessed using criteria that included method of randomization, concealment of allocation, completeness of follow-up, and blinding of outcome assessment. In patients with a history of ischemic cerebrovascular disease, dipyridamole given with or without aspirin reduces the risk for recurrent stroke.
ACCESSION #
18053693

 

Related Articles

  • Does aspirin protect against Alzheimer's dementia? A study in a Swedish population-based sample aged ≥80 years. Nilsson, Sven E.; Johansson, Boo; Takkinen, Sanna; Berg, Stig; Zarit, Steven; McClearn, Gerald; Melander, Arne // European Journal of Clinical Pharmacology;Aug2003, Vol. 59 Issue 4, p313 

    Objective. It has been reported that aspirin and other non-steroidal anti-inflammatory drugs (NSAID) may protect against dementia of Alzheimer's type and/or vascular dementia. However, co-morbidity and the dose of aspirin may be critical. A major indication for low-dose aspirin is prophylaxis...

  • Aspirin non-responder status in patients with recurrent cerebral ischemic attacks. Grundmann, K.; Jaschonek, K.; Kleine, B.; Dichgans, J.; Topka, H. // Journal of Neurology;Jan2003, Vol. 250 Issue 1, p63 

    Background: Antiplatelet agents such as acetylsalicylic acid (aspirin) reduce the relative risk for cerebrovascular events in patients with cardiovascular or cerebrovascular disorders by approximately 23 %. Recent observations raise the possibility that aspirin resistance may contribute to the...

  • Aspirin plus extended-release dipyridamole and clopidogrel were similarly effective for preventing recurrent stroke. Sacco, R. L. // Evidence Based Medicine;Apr2009, Vol. 14 Issue 2, p46 

    The article discusses the study of similar effectiveness of aspirin and plus extended-release dipyridamole (ERDP) and clopidogrel in the prevention of recurrent stroke in the U.S. The patients having the similar usage had an ischaemic stroke previously were notably stable clinically and...

  • A Randomized Trial of E5510 versus Aspirin in Patients with Transient Ischemic Attacks. Maruyama, Shoichi; Uchiyama, Shinichiro; Tohgi, Hideo; Hirai, Shunsaku; Ikeda, Yasuo; Shinohara, Yukito; Matsuda, Tamotsu; Fujishima, Masatoshi; Kameyama, Masakuni // Angiology;Nov1995, Vol. 46 Issue 11, p999 

    In a randomized double-blind trial, the Study Group compared the efficacy of E5510, a novel antiplatelet agent, and aspirin in preventing the recurrence of transient ischemic attacks (TIA). In total, 227 patients who suffered from TIA in the twelve weeks prior to the study were enrolled. They...

  • Primary and Secondary Stroke Prevention with Antiplatelet Drugs. Diener, Hans-Christoph // Current Pharmaceutical Design;Apr2006, Vol. 12 Issue 10, p1293 

    Aspirin is not effective in the primary prevention of stroke. Patients with TIA or ischemic stroke carry a risk of recurrent stroke between 5 and 20% per year. In patients with TIA or ischemic stroke of noncardiac origin antiplatelet drugs are able to decrease the risk of stroke by 11-15% and...

  • Aspirin for the next generation. Henderson, Nick; Smith, Tom // Ecancermedicalscience;2013, Vol. 7, p1 

    First used as an analgesic and antipyretic, investigations into aspirin's anti-inflammatory effects led to its establishment in 1974 as a drug that altered the activity of platelets to influence the course and incidence of myocardial infarction and cerebrovascular disease. It became the standard...

  • Review of Antiplatelet Therapy in Secondary Prevention of Cerebrovascular Events: A Need for Direct Comparisons Between Antiplatelet Agents. Jamieson, Dara G.; Parekh, Amit; Ezekowitz, Michael D. // Journal of Cardiovascular Pharmacology & Therapeutics;Sep2005, Vol. 10 Issue 3, p153 

    Evaluates the use of antiplatelet agents for patients with a history of noncardioembolic stroke or transient ischemic attack. Prevalence of stroke patients in the U.S.; Assertion that antiplatelet agents is one of the most important mainstays of secondary stroke prevention; Comparison of the...

  • What to Know About Aspirin Therapy.  // National Women's Health Report;Feb2005, Vol. 27 Issue 1, p5 

    Provides information about aspirin therapy in the U.S. Connection between aspirin and heart attack prevention; Risk of gastrointestinal bleeding in taking aspirin; Recommendation for people at high risk for heart attack or stroke to take aspirin.

  • Postmyocardial Patients Using Aspirin and Stroke Prevention. Sadovsky, Richard // American Family Physician;3/1/2002, Vol. 65 Issue 5, p935 

    Presents information on a study by C.M. O'Connor and others to compare stroke prevention with 80 mg of aspirin and 160 mg of aspirin, using data from the Coumadin Aspirin Reinfarction Study. Description of the study and its results; Conclusion that many postmyocardial infarction patients are...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics